Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab - Randomized, Open-label, in Parallel Arms, Head to Head Trial

NCT07836283 is registered in ClinicalTrials.gov with University Hospital, Rouen as lead sponsor.

NCT NCT07836283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07836283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab - Randomized, Open-label, in Parallel Arms, Head to Head Trial
Lead sponsor
University Hospital, Rouen
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
October 15, 2030
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

axial or predominantly axial spondyloarthritis with or without psoriasis